Current status and prospect for future advancements of long-acting antibody formulations

References

• Hodgson J. Refreshing the biologic pipeline 2020. Nat Biotechnol. 2021 Feb;39(2):135–143. PubMed PMID: 33510484; PubMed Central PMCID: PMCPMC7842168. DOI:10.1038/s41587-021-00814-w
   PubMed Web of Science ®Google Scholar
• cited 5 Oct 2022. Available from: https://www.antibodysociety.org/resources/approved-antibodies/.
   Google Scholar
• cited 5 Oct 2022. Available from: https://www.researchandmarkets.com/reports/5553704/biologics-global-market-report-2022-by-type-by?.
   Google Scholar
• Dunleavy, K. 2022 May 31. cited 5 Oct 2022. Available from: https://www.fiercepharma.com/special-reports/top-20-drugs-worldwide-sales-2021.
   Google Scholar
• Berger J, Dunn JD, Johnson MM, et al. How drug life-cycle management patent strategies may impact formulary management. Am J Manag Care. 2016;22(16):S487–S495.
   PubMed Web of Science ®Google Scholar
• Daidoji K, Yasukawa S, Kano S. Effects of new formulation strategy on life cycle management in the US pharmaceutical industry. Journal Of Generic Medicines. 2014;10(3–4):172–179.
   Google Scholar
• Gupta V, Bhavanasi S, Quadir M, et al. Protein PEGylation for cancer therapy: bench to bedside. J Cell Commun Signal. 2019 Sep;13(3):319–330. PubMed PMID: 30499020; PubMed Central PMCID: PMCPMC6732144. DOI:10.1007/s12079-018-0492-0
   PubMed Web of Science ®Google Scholar
• Jevsevar S, Kunstelj M, Porekar VG. Pegylation of therapeutic proteins. Biotechnol J. 2010 Jan;5(1):113–128. PubMed PMID: 20069580. DOI:10.1002/biot.200900218
   PubMed Web of Science ®Google Scholar
• Morgenstern J, Baumann P, Brunner C, et al. Effect of PEG molecular weight and PEGylation degree on the physical stability of PEGylated lysozyme. Int J Pharm. 2017 Mar 15;519(1–2):408–417. PubMed PMID: 28130198. DOI:10.1016/j.ijpharm.2017.01.040
   PubMedGoogle Scholar
• Yang B, Gomes Dos Santos A, Puri S, et al. The industrial design, translation, and development strategies for long-acting peptide delivery. Expert Opin Drug Deliv. 2022 Jul;21:1–13. PubMed PMID: 35787229. DOI: 10.1080/17425247.2022.2098276
   Google Scholar
• Brown MT, Bussell JK. Medication adherence: wHO cares? Mayo Clin Proc. 2011 Apr;86(4):304–314. PubMed PMID: 21389250; PubMed Central PMCID: PMCPMC3068890. DOI:10.4065/mcp.2010.0575
   PubMed Web of Science ®Google Scholar
• Stoddard A, McNicholas C, Peipert JF. Efficacy and safety of long-acting reversible contraception. Drugs. 2011;71(8):969–980.
   PubMed Web of Science ®Google Scholar
• Divino V, Boye KS, Lebrec J, et al. GLP-1 RA treatment and dosing patterns among type 2 diabetes patients in six countries: a retrospective analysis of pharmacy claims data. Diabetes Ther. 2019 Jun;10(3):1067–1088. PubMed PMID: 31028689; PubMed Central PMCID: PMCPMC6531601. DOI:10.1007/s13300-019-0615-5
   PubMed Web of Science ®Google Scholar
• Blankenship, K. 2019 Oct 31. cited 25 Oct 2022. Available from: https://www.fiercepharma.com/pharma/alexion-s-soliris-sales-booming-despite-unprecedented-switching-success.
   Google Scholar
• Bydureon Prescribing Information. cited 6 Oct 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022200s026lbl.pdf.
   Google Scholar
• LUCENTIS™ (ranibizumab injection) Prescribing Information. cited 5 Oct 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125156lbl.pdf.
   Google Scholar
• Campochiaro PA, Marcus DM, Awh CC, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 ladder clinical trial. Ophthalmol. 2019 Aug;126(8):1141–1154. PubMed PMID: 30946888. DOI:10.1016/j.ophtha.2019.03.036
   PubMed Web of Science ®Google Scholar
• Fu AZ, Pesa JA, Lakey S, et al. Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia. BMC Psychiatry. 2022 Apr 9;22(1):250. PubMed PMID: 35395757; PubMed Central PMCID: PMCPMC8994268. DOI:10.1186/s12888-022-03895-2
   PubMed Web of Science ®Google Scholar
• Manjelievskaia J, Amos TB, El Khoury AC, et al. A comparison of treatment patterns, healthcare resource utilization, and costs among young adult Medicaid beneficiaries with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in the US. J Med Econ. 2018 Dec;21(12):1221–1229. PubMed PMID: 30238806. DOI:10.1080/13696998.2018.1527608
   PubMed Web of Science ®Google Scholar
• Shah A, Xie L, Kariburyo F, et al. Treatment patterns, healthcare resource utilization and costs among schizophrenia patients treated with long-acting injectable versus oral antipsychotics. Adv Ther. 2018 Nov;35(11):1994–2014. PubMed PMID: 30269292. DOI:10.1007/s12325-018-0786-x
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A. Mechanisms influencing the pharmacokinetics and disposition of monoclonal antibodies and peptides. Drug Metab Dispos. 2019 Oct;47(10):1100–1110. PubMed PMID: 31043438. DOI:10.1124/dmd.119.086488
   PubMed Web of Science ®Google Scholar
• Worth CL, Gong S, Blundell TL. Structural and functional constraints in the evolution of protein families. Nat Rev Mol Cell Biol. 2009 Oct;10(10):709–720. PubMed PMID: 19756040. DOI:10.1038/nrm2762
   PubMed Web of Science ®Google Scholar
• Kang TH, Jung ST. Boosting therapeutic potency of antibodies by taming Fc domain functions. Exp Mol Med. 2019 Nov 18;51(11):1–9. PubMed PMID: 31735912; PubMed Central PMCID: PMCPMC6859160. DOI:10.1038/s12276-019-0345-9
   Google Scholar
• Shen Y, Li H, Zhao L, et al. Increased half-life and enhanced potency of Fc-modified human PCSK9 monoclonal antibodies in primates. PLoS ONE. 2017;12(8):e0183326. PubMed PMID: 28817679; PubMed Central PMCID: PMCPMC5560549. DOI:10.1371/journal.pone.0183326
   PubMed Web of Science ®Google Scholar
• Robbie GJ, Criste R, Dall’acqua WF, et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother. 2013 Dec;57(12):6147–6153. PubMed PMID: 24080653; PubMed Central PMCID: PMCPMC3837853. DOI:10.1128/AAC.01285-13
   PubMed Web of Science ®Google Scholar
• Digiandomenico A, Dippel A, Varkey R, et al. Identification of a new IgG mAb format with enhanced complement mediated effector function and extended half life. Am J Respir Crit Care Med. 2022;205:A4648.
   Web of Science ®Google Scholar
• Castillo RR, Lozano D, Gonzalez B, et al. Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery: an update. Expert Opin Drug Deliv. 2019 Apr;16(4):415–439. PubMed PMID: 30897978; PubMed Central PMCID: PMCPMC6667337. DOI:10.1080/17425247.2019.1598375
   PubMed Web of Science ®Google Scholar
• Vallet-Regi M, Colilla M, Izquierdo-Barba I, et al. Mesoporous silica nanoparticles for drug delivery: current insights. Molecules. 2017 Dec 25;23(1). PubMed PMID: 29295564; PubMed Central PMCID: PMCPMC5943960. DOI: 10.3390/molecules23010047
   Web of Science ®Google Scholar
• Popplewell JF, King SJ, Day JP, et al. Kinetics of uptake and elimination of silicic acid by a human subject: a novel application of 32Si and accelerator mass spectrometry. J Inorg Biochem. 1998 Feb 15;69(3):177–180. PubMed PMID: 9629677. DOI:10.1016/s0162-0134(97)10016-2
   PubMed Web of Science ®Google Scholar
• Issa AA, El-Azazy M, Luyt AS. Kinetics of alkoxysilanes hydrolysis: an empirical approach. Sci Rep. 2019 Nov 26;9(1):17624. PubMed PMID: 31772267; PubMed Central PMCID: PMCPMC6879604. DOI:10.1038/s41598-019-54095-0
   PubMedGoogle Scholar
• Tyagi P, Koskinen M, Mikkola J, et al. Silica microparticles for sustained zero-order release of an anti-CD40L antibody. Drug Deliv Transl Res. 2018 Apr;8(2):368–374. PubMed PMID: 28752299. DOI:10.1007/s13346-017-0408-1
   PubMed Web of Science ®Google Scholar
• Liu HC, Viswanath DI, Pesaresi F, et al. Potentiating antitumor efficacy through radiation and sustained intratumoral delivery of anti-CD40 and Anti-PDL1. Int J Radiat Oncol Biol Phys. 2021 Jun 1;110(2):492–506. PubMed PMID: 32768562; PubMed Central PMCID: PMCPMC8547413. DOI:10.1016/j.ijrobp.2020.07.2326
   PubMed Web of Science ®Google Scholar
• Di Trani N, Silvestri A, Sizovs A, et al. Electrostatically gated nanofluidic membrane for ultra-low power controlled drug delivery. Lab Chip. 2020 May 5;20(9):1562–1576. PubMed PMID: 32249279; PubMed Central PMCID: PMCPMC7249613. DOI:10.1039/d0lc00121j
   PubMed Web of Science ®Google Scholar
• Liu HC, Davila Gonzalez D, Viswanath DI, et al. Sustained intratumoral administration of agonist CD40 antibody overcomes immunosuppressive tumor microenvironment in pancreatic cancer. Adv Sci. 2023 Mar;10(9):e2206873. PubMed PMID: 36658712; PubMed Central PMCID: PMCPMC10037694. DOI:10.1002/advs.202206873
   Google Scholar
• Woodruff MA, Hutmacher DW. The return of a forgotten polymer. Polycaprolactone in the 21st century. Prog Polym Sci. 2010;35:1217–1256.
   Web of Science ®Google Scholar
• Labet M, Thielemans W. Synthesis of polycaprolactone: a review. Chem Soc Rev. 2009 Dec;38(12):3484–3504. PubMed PMID: 20449064. DOI:10.1039/b820162p
   PubMed Web of Science ®Google Scholar
• Park JH, Lee BK, Park SH, et al. Preparation of biodegradable and elastic Poly(ε-caprolactone-co-lactide) copolymers and evaluation as a localized and sustained drug delivery carrier. Int J Mol Sci. 2017 Mar 21;18(3):671. PubMed PMID: 28335550; PubMed Central PMCID: PMCPMC5372682. DOI:10.3390/ijms18030671
   PubMed Web of Science ®Google Scholar
• YpsoDose® single-use injector. cited 5 Oct 2022. Available from: https://yds.ypsomed.com/en/products/wearable-injectors/ypsodose.html.
   Google Scholar
• cited 11 Oct 2022. Available from: https://xerispharma.com/research-development/technology.
   Google Scholar
• cited 11 Oct 2022. Available from: https://www.elektrofi.com/welcome#technology.
   Google Scholar
• cited 11 Oct 2022. Available from: https://www.lindybio.com/technology.
   Google Scholar
• Badkar AV, Gandhi RB, Davis SP, et al. Subcutaneous delivery of high-dose/volume biologics: current status and prospect for future advancements. Drug Des Devel Ther. 2021;15:159–170. PubMed PMID: 33469268; PubMed Central PMCID: PMCPMC7812053. DOI:10.2147/DDDT.S287323
   PubMed Web of Science ®Google Scholar